US ▾
ISPR
Earnings call · Jun 2026 (Q4 FY26)

Ispire Technology Q4 FY26 earnings call ISPR

Sep 16, 2026 Source

Executive summary

Ispire Technology Inc. Q4 FY26 — Turnaround Inflection Point with Revenue Growth and Strategic Expansion

Ispire Technology reached an inflection point in its turnaround, marked by significant Q4 revenue growth and a leaner cost structure. The company is strategically expanding its manufacturing capabilities in Malaysia with new licenses and advancing its IKE Tech platform for age verification and product authentication. Fiscal 2027 is anticipated to be a transformational year, focusing on commercializing new capacities and technologies, despite planned investments impacting short-term cash flow positivity.

Highlights

5

  • Q4 revenue increased 33% year-over-year and 43% sequentially to $26.7 million.

  • Operating expenses (excluding credit loss) decreased 28.6% year-over-year to $6 million in Q4.

  • Adjusted EBITDA loss improved by $2.1 million year-over-year to -$2.3 million in Q4.

  • Operating cash used improved by $6.8 million year-over-year to -$569,000 for FY26.

  • Secured nicotine manufacturing licenses for vapor (March 2026) and pouches (May 2026) in Malaysia.

Concerns

5

  • Q4 gross margin declined to 6.3% from 12.3% year-over-year due to inventory impairment.

  • FY26 revenue decreased to $96 million from $127.5 million in FY25.

  • FY26 gross margin declined to 12.8% from 70.8% in FY25 due to product mix and one-time inventory provision.

  • Cash balance decreased to $19.3 million at year-end FY26 from $24.4 million in FY25.

  • Remaining legacy account receivable write-offs are expected to be substantially addressed during fiscal 2027.

Guidance & targets

CategoryTargetConfidence
Malaysia manufacturing production
First fiscal year of vapor and nicotine production at company-owned facilities
high materiality
High
Legacy account receivable write-offs
Substantially addressed with little or no carryover
medium materiality
High
Commercial agreements from Malaysia opportunities
Several opportunities will mature and translate into commercial agreements
high materiality
Medium
IKE 2.0 launch
Launch this fall
medium materiality
High
IKE liquidity event
Potential path to a significant liquidity event
high materiality
Medium
Malaysia orders maturity
Orders will really start to mature over the next 2 quarters
high materiality
Medium
PMTA process results
See some really good results on that process
high materiality
Medium

Product announcements

ProductTypeDetails
IKE 2.0launch

Capital programs

Malaysia manufacturing facility expansion underway
Period spend: significant payments
Start: Post-March/May 2026 license approvals

Benefit:additional production capacity; second factory can fit up to 73 lines; ability to scale to hundreds of millions of units

Planned investments in capacity for automated lines and workforce, contingent on securing manufacturing licenses for vapor and nicotine pouches in March and May 2026, respectively. These investments are expected to impact cash flow positive timeline in FY27.

Risks & headwinds

Financial cleanup and legacy account receivables FY27

Remaining legacy account receivable write-offs to be substantially addressed during fiscal 2027

Mitigation:Continued discipline around receivables and working capital management

Gross margin decline Q4 FY26, FY26

Q4 gross margin declined to 6.3% from 12.3% YoY; FY26 gross margin declined to 12.8% from 70.8% in FY25

Mitigation:Addressing product mix and one-time inventory provision; leveraging revenue growth and scale to drive operating improvements

Impact of Malaysia investments on cash flow positive timeline FY27

Significant payments related to Malaysia manufacturing facility

Mitigation:Planned investments in capacity that are important for growth strategy; underlying cash operating performance has improved substantially

What to watch in Q1 FY27

Malaysia manufacturing commercial agreements

next 2 quarters
Current Pilot runs, initial orders, reorders from OEM/ODM customers
Target Several opportunities mature into commercial agreements

Why it matters

Key driver for new revenue streams and utilization of new Malaysian capacity, crucial for the company's growth strategy.

Our expectation is that several of these opportunities will mature and translate into commercial agreements during fiscal 2027.

Q&A highlights

Has the incorporation of age-gating technology into supplemental PMTAs accelerated, given recent FDA approvals and the IKE platform?

Discussions with every player with an authorized ENDS device have occurred, some progressing to pilot evaluations. There is significant interest in amending PMTAs to include Ispire's modular age-gating technology, with a potential pathway to supplemental approvals with one or two players in the near term.

“We believe we're the only 1 with the modular technology that you can drop in and then update your device with here. So, supplemental certainly are the flavor right now. We believe we've got a pathway to a supplemental with perhaps 1 or 2 players here.”

asked by Nick Anderson · answered by Unknown Speaker

2 min read 5 chapters

Detailed narrative

Turnaround Progress and Financial Cleanup

Ispire Technology has reached an inflection point in its turnaround strategy, initiated over a year ago. The company focused on shoring up its balance sheet, reducing cost structure, and addressing legacy issues. This work is now reflected in financial results, with Q4 revenue up 33% year-over-year and operating expenses substantially lower. The financial cleanup, including legacy account receivable write-offs, is expected to be largely completed in fiscal 2027, positioning the company for positive GAAP earnings.

Malaysia Manufacturing Expansion and Market Opportunity

Fiscal 2027 will mark the first full year of vapor and nicotine pouch production at Ispire's company-owned facilities in Malaysia, following license approvals in March and May 2026. This expansion provides additional production capacity and changes the economics of the manufacturing business. The company is seeing strong interest from Chinese brands seeking to diversify production outside China and from major global tobacco companies, with expectations for commercial agreements to mature in FY27.

IKE Tech and Regulatory Strategy

IKE Tech is developing into a broader technology platform focused on age verification, product authentication, and compliance for regulated nicotine markets. The company has engaged with the FDA, receiving positive feedback on its age-gating technology, and IKE 2.0 is scheduled to launch this fall. While the component PMTA remains under review, Ispire is pursuing commercial partnerships and exploring a potential significant liquidity event for IKE in fiscal 2027, independent of regulatory authorization.

G-MESH and Future Transformational Investments

Beyond IKE, G-MESH technology continues to generate interest from leading global tobacco companies and international brands, offering potential product differentiation. Ispire is also actively evaluating transformational investments in disruptive technologies. The focus is on opportunities where the company's capital, manufacturing expertise, regulatory infrastructure, or global relationships can create a meaningful advantage and accelerate its evolution into a technology-forward company.

Fiscal 2027 Outlook and Execution Focus

Management anticipates fiscal 2027 to be a defining year, building on a stronger foundation with a leaner cost structure and cleaner balance sheet. Key priorities include bringing new manufacturing capacity online, converting commercial opportunities into revenue, and advancing technology platforms. While significant planned investments in the Malaysia facility may impact the timeline for achieving cash flow positive, the underlying cash operating performance has substantially improved.

AI-generated summary of the company's earnings call. Not investment advice.